The global glucagon-like peptide-1 analogues market, valued at US$62.81 billion in 2024, is projected to reach US$299.08 billion by 2033 at a 17.6% CAGR. Explore drivers like rising obesity and type 2 diabetes prevalence, innovative pipelines including CagriSema, and expansions in chronic weight management amid healthcare spending growth. https://finance.yahoo.com/news/glucagon-peptide-1-analogues-market-140100995.html